---
company: Sabra Health Care REIT, Inc.
ticker: SBRA
form: 8-K
filed: 2026-11-02
accepted: 2026-11-02T21:05:33+00:00
accession: 0001492298-26-000032
source: https://www.sec.gov/Archives/edgar/data/1492298/000149229826000032/
---

# Sabra Health Care REIT (SBRA) Q3 2026 earnings

## Header

- Company: Sabra Health Care REIT, Inc.
- Reported: 2026-11-02 16:05 AMC ET
- Source: 8-K only — accession 0001492298-26-000032, Item 2.02 + Exhibit 99.1
- Verdict: Net income turned positive at $0.11 per share, with AFFO reaching $0.45 per share, supported by strong SHOP Cash NOI growth of 14.6% and robust investment activity.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---:|---:|---|
| Revenue | $249.6M | +31.4% | +5.9% | Ex. 99.1, income statement |
| EPS (GAAP) | $0.11 | +22.2% | +110.0% | Ex. 99.1, income statement |

## Revenue breakdown

| Segment | Actual | YoY | Share of revenue | Note |
|---|---:|---:|---:|---|
| Rental and related revenues | $103.2M | +20.9% | 41.3% | — |
| Resident fees and services | $143.2M | +55.5% | 57.4% | — |
| Interest and other income | $3.2M | -74.6% | 1.3% | — |

## Margins and costs

- Gross margin: N/A
- Operating expenses: $214.9M (+31.9% YoY)
- One-offs in the quarter: Impairment of real estate; Loss on extinguishment of debt; Provision for loan losses and other reserves ($2.4M); Other normalizing items ($9.0M)
- Effective tax rate: 0.2% (prior-year 2.0%, year-to-date 2.9%)
- Non-GAAP bridge: Adds back depreciation, amortization, impairment, loss on debt extinguishment, loan losses, stock-based comp, non-cash rental/interest, and other adjustments to GAAP net income to arrive at FFO and AFFO.

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---|---:|
| Net Debt to Adjusted EBITDA | 4.54x | 4.61x | N/A | -0.07x |
| SHOP Cash NOI growth | 14.6% | 13.7% | N/A | +0.9 pp |
| EBITDARM Coverage - Skilled Nursing/Transitional Care | 2.52x | 2.49x | N/A | +0.03x |
| EBITDARM Coverage - Senior Housing - Leased | 1.58x | 1.52x | N/A | +0.06x |
| EBITDARM Coverage - Specialty Hospitals and Other | 3.91x | 4.14x | N/A | -0.23x |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---:|---:|---|
| Net Income | $0.265 - $0.275 | $0.265 - $0.275 | N/A |
| FFO | $1.145 - $1.155 | $1.145 - $1.155 | N/A |
| Normalized FFO | $1.540 - $1.550 | $1.540 - $1.550 | N/A |
| AFFO | $1.625 - $1.635 | $1.625 - $1.635 | N/A |
| Normalized AFFO | $1.600 - $1.610 | $1.600 - $1.610 | N/A |

## What drove it

- Revenue story: Resident fees and services grew 55.5% YoY to $143.2M, while rental and related revenues grew 20.9% YoY to $103.2M. Interest and other income declined 74.6% YoY to $3.2M.
- EPS story: EPS moved from a loss of $(0.10) in Q2 to a gain of $0.11, driven by improved operating margins, lower interest expense, and lower tax rates.
- One-off check: Impairment of real estate and loss on extinguishment of debt ($1.2M) are non-recurring items impacting the quarter.

## The good

- Net income turned positive at $0.11 per share
- SHOP Cash NOI growth accelerated to 14.6%
- EBITDARM coverage for Skilled Nursing/Transitional Care increased to 2.52x
- Investments closed year to date reached $747.2M

## The bad

- Interest and other income declined 74.6% YoY
- Senior Housing - Leased coverage dropped to 1.58x
- Specialty Hospitals and Other coverage dropped to 3.91x

## The ugly

- none

## Open questions

- The release does not provide a reconciliation of the $63M G&A expense assumption to the actual $15.6M reported in the quarter.
- The release does not disclose the specific impact of the Avamere transition on the SHOP portfolio's operating metrics.
- The release does not provide a breakdown of the $425M of awarded investments by property type.

## Full release

### Sabra Health Care REIT (SBRA) earnings release, November 2, 2026

Sabra Health Care REIT, Inc. (SBRA) · Form 8-K, Item 2.02 · Filed 2026-11-02 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1492298/000149229826000032/)

SABRA REPORTS THIRD QUARTER 2026 RESULTS; UPDATES 2026 GUIDANCE

TUSTIN, CA, November 2, 2026 — Sabra Health Care REIT, Inc. (“Sabra,” the “Company” or “we”) (Nasdaq: SBRA) today announced its results of operations for the third quarter of 2026.

THIRD QUARTER 2026 RESULTS

• Results per diluted common share for the third quarter of 2026 were as follows:

• Net Income: $0.11

• FFO: $0.40

• Normalized FFO: $0.39

• AFFO: $0.45

• Normalized AFFO: $0.41

• EBITDARM Coverage Summary:

• Skilled Nursing/Transitional Care: 2.52x

• Senior Housing - Leased: 1.58x

• Specialty Hospitals and Other: 3.91x

• On a year-over-year basis, same property Senior Housing Operating Portfolio (“SHOP”) Cash NOI increased 14.6% for the third quarter of 2026.

INVESTMENTS AND PORTFOLIO ACTIVITY

• As previously announced, Sabra closed on the acquisition of seven SHOP communities for an aggregate price of $222.8 million in the third quarter with an estimated yield of 7.7%.

• Investments closed year to date total $747.2 million, with an estimated yield of 8.0%.

• Sabra has been awarded an additional $425 million of investments, of which about $385 million is SHOP, $25 million is skilled nursing and $15 million is preferred equity, with an estimated yield of 7.0%. These investments are currently in the Letter of Intent or later stage, and Sabra expects to fund these investments, if consummated, with available liquidity, including proceeds from outstanding forward sales agreements under its at-the-market equity offering program (“ATM program”).

• Sabra’s closed and awarded SHOP investments are expected to generate unlevered IRRs in the low-teens, providing for strong current income and the potential for outsized future earnings growth.

• On October 1, 2026, Sabra completed the previously announced transition of 26 properties formerly leased to Avamere, with 22 properties being transitioned to subsidiaries of Cascadia Healthcare and four properties being transitioned to subsidiaries of the Ensign Group. As a result of this transition, effective October 1, 2026, annualized cash rent for these properties increased to $53 million from $48 million.¹

OTHER RECENT EVENTS

• During the third quarter of 2026, Sabra utilized the forward feature of the ATM program to allow for the sale of up to 0.1 million shares of the Company’s common stock at an initial weighted average price of $19.94 per share. As of September 30, 2026, 15.0 million shares remained outstanding under forward sale agreements at a weighted average price of $19.53 per share, net of commissions.

• As of September 30, 2026, Net Debt to Adjusted EBITDA was 4.54x.

• On November 2, 2026, Sabra’s Board of Directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on November 30, 2026, to common stockholders of record as of the close of business on November 13, 2026.

UPDATED FULL-YEAR 2026 GUIDANCE

Sabra is updating its 2026 earnings guidance ranges as follows (attributable to Sabra Health Care REIT, Inc., per diluted common share):

• Net Income: $0.265 - $0.275

• FFO: $1.145 - $1.155

• Normalized FFO: $1.540 - $1.550

• AFFO: $1.625 - $1.635

• Normalized AFFO: $1.600 - $1.610

Earnings guidance above assumes:

• low-single-digit Cash NOI growth for the triple-net portfolio at the midpoint, ignoring the impact of acquisitions, dispositions and completed or planned tenant transitions;

• average full-year Cash NOI growth for same store SHOP in the mid-teens;

• general and administrative expenses at the midpoint of $63 million, which includes nearly $15 million of stock-based compensation expense;

• cash interest expense of $106 million at the midpoint;

• weighted average share counts of 260 million and 261 million for Normalized FFO and Normalized AFFO, respectively;

• only investments, dispositions and capital markets activity already completed as of the date of this release.

The foregoing guidance ranges reflect management’s view of current and future market conditions. There can be no assurance that the Company’s actual results will not differ materially from the estimates set forth above. Except as otherwise required by law, the Company assumes no, and hereby disclaims any, obligation to update any of the foregoing guidance ranges as a result of new information or new or future developments.

Commenting on the third quarter’s results, Rick Matros, CEO and Chair, said, “Sabra delivered another strong quarter. Same store SHOP Cash NOI margins and REVPOR growth are among the best in the space accompanied by solid occupancy and cash NOI growth. Investment activity continues to be robust, with $425 million currently awarded and more expected to come before year end. We expect our SHOP concentration to be around 40% on a run rate basis by year end 2026 and 50% by the end of 2027. We continue to evaluate our skilled nursing portfolio for optimization opportunities along the lines of our July announcement.

Our triple-net skilled nursing and senior housing portfolios again showed increased rent coverage. Leverage ticked down, and we increased our guidance at the midpoint. We do not foresee any barriers that would slow down our current momentum and the shift in our portfolio mix to be more heavily weighted towards SHOP, which will continue to be supported by an exceptionally strong triple-net skilled nursing portfolio.”²

LIQUIDITY

As of September 30, 2026, we had approximately $1.2 billion of liquidity, consisting of unrestricted cash and cash equivalents of $36.2 million, available borrowings under our revolving credit facility of $873.5 million and $292.5 million related to shares outstanding under forward sale agreements under the ATM program. As of September 30, 2026, we also had $332.7 million available under our ATM program.

CONFERENCE CALL AND COMPANY INFORMATION... (truncated)esday, November 3, 2026, at 10:00 am Pacific Time. The webcast URL is https://events.q4inc.com/attendee/325673757. The dial-in number for U.S. participants is (833) 461-5787. For participants outside the U.S., the dial-in number is (585) 542-9983. The conference ID number is 325673757. A digital replay of the call will be available on the Company’s website at www.sabrahealth.com. The Company’s supplemental information package for the third quarter will also be available on the Company’s website in the “Investors” section.

ABOUT SABRA

As of September 30, 2026, Sabra’s investment portfolio included 364 real estate properties held for investment (consisting of (i) 207 skilled nursing/transitional care facilities, (ii) 32 senior housing communities (“senior housing - leased”), (iii) 24 specialty hospitals and other facilities and (iv) 101 senior housing communities operated by third-party property managers pursuant to property management agreements (“senior housing operating portfolio” or “SHOP”)), 11 investments in loans receivable (consisting of two mortgage loans and nine other loans), four preferred equity investments and two investments in unconsolidated joint ventures. As of September 30, 2026, Sabra’s real estate properties held for investment included 37,513 beds/units, spread across the United States and Canada.

FORWARD-LOOKING STATEMENTS SAFE HARBOR

This release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Any statements that do not relate to historical or current facts or matters are forward-looking statements. These statements may be identified, without limitation, by the use of “expects,” “believes,” “intends,” “should” or comparable terms or the negative thereof. Examples of forward-looking statements include all statements regarding our other expectations regarding our future financial position (including our earnings guidance for 2026, as well as the assumptions set forth therein); our expectations regarding our results of operations, cash flows, liquidity, business strategy, growth opportunities, potential investments and dispositions; our expectations regarding our investment activity; and our plans and objectives for future operations.

Our actual results may differ materially from those projected or contemplated by our forward-looking statements as a result of various factors, including, among others, the following: the ability to reach a definitive agreement for awarded investments and our ability to close such acquisitions on the expected terms or at all; increases in market interest rates and inflation; pandemics or epidemics, and the related impact on our tenants, borrowers and SHOP communities; operational risks with respect to our SHOP communities; increased labor costs and labor shortages; competitive conditions in our industry; the loss of key management personnel; uninsured or underinsured losses affecting our properties; potential impairment charges and adjustments related to the accounting of our assets; risks associated with our investment in our unconsolidated joint ventures; catastrophic weather and other natural or man-made disasters, the effects of climate change on our properties and a failure to implement sustainable and energy-efficient measures; increased operating costs and competition for our tenants, borrowers and SHOP communities; increased healthcare regulation and enforcement; our tenants’ dependency on reimbursement from governmental and other third-party payor programs; the effect of our tenants, operators or borrowers declaring bankruptcy or becoming insolvent; our ability to find replacement tenants and the impact of unforeseen costs in acquiring new properties; the impact of litigation and rising insurance costs on the business of our tenants; the impact of required regulatory approvals of transfers of healthcare properties; environmental compliance costs and liabilities associated with real estate properties we own; our tenants’, borrowers’ or operators’ failure to adhere to applicable privacy and data security laws; a material breach of our or our tenants’, borrowers’ or operators’ information technology; our concentration in the healthcare property sector, particularly in skilled nursing/transitional care facilities and senior housing communities, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries; the significant amount of and our ability to service our indebtedness; covenants in our debt agreements that may restrict our ability to pay dividends, make investments, incur additional indebtedness and refinance indebtedness on favorable terms; adverse changes in our credit ratings; our ability to make dividend distributions at expected levels; our ability to raise capital through equity and debt financings; changes and uncertainty in macroeconomic conditions and disruptions in the financial markets; risks associated with our ownership of³ property outside the U.S., including currency fluctuations; the relatively illiquid nature of real estate investments; our ability to maintain our status as a real estate investment trust (“REIT”) under the federal tax laws; compliance with REIT requirements and certain tax and tax regulatory matters related to our status as a REIT; changes in tax laws and regulations affecting REITs; the ownership limits and takeover defenses in our governing documents and under Maryland law, which may restrict change of control or business combination opportunities; and the exclusive forum provisions in our bylaws.... (truncated)mation to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, unless required by law to do so.

TENANT AND BORROWER INFORMATION

This release includes information regarding certain of our tenants that lease properties from us and our borrowers, most of which are not subject to SEC reporting requirements. The information related to our tenants and borrowers that is provided in this release has been provided by, or derived from information provided by, such tenants and borrowers. We have not independently verified this information. We have no reason to believe that such information is inaccurate in any material respect. We are providing this data for informational purposes only.

NOTE REGARDING NON-GAAP FINANCIAL MEASURES

This release includes the following financial measures defined as non-GAAP financial measures by the SEC: Net Debt to Adjusted EBITDA, funds from operations (“FFO”), Normalized FFO, Adjusted FFO (“AFFO”), Normalized AFFO, FFO per diluted common share, Normalized FFO per diluted common share, AFFO per diluted common share, Normalized AFFO per diluted common share, net operating income (“NOI”) and Cash NOI. These measures may be different than non-GAAP financial measures used by other companies, and the presentation of these measures is not intended to be considered in isolation or as a substitute for financial information prepared and presented in accordance with U.S. generally accepted accounting principles. An explanation of these non-GAAP financial measures is included under “Reporting Definitions” in this release, and reconciliations of these non-GAAP financial measures to the GAAP financial measures we consider most comparable are included on the Investors section of our website at https://ir.sabrahealth.com/investors/financials/quarterly-results.

CONTACT

Investor & Media Inquiries: (888) 393-8248 or investorinquiries@sabrahealth.com⁴

#### Financial statements

##### Income Statement (Three Months Ended September 30, — (dollars in thousands, except per share data))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| **Revenues:** | | | | |
| Rental and related revenues (1) | 103,178 | 85,354 | 299,536 | 281,214 |
| Resident fees and services | 143,164 | 92,017 | 388,651 | 248,449 |
| Interest and other income | 3,223 | 12,666 | 18,997 | 33,067 |
| Total revenues | 249,565 | 190,037 | 707,184 | 562,730 |
| **Expenses:** | | | | |
| Depreciation and amortization | 64,779 | 48,511 | 174,289 | 135,591 |
| Interest | 29,161 | 28,901 | 87,349 | 83,549 |
| Triple-net portfolio operating expenses | 3,658 | 3,708 | 11,087 | 10,885 |
| Senior housing operating portfolio operating expenses | 99,302 | 65,946 | 269,787 | 179,804 |
| General and administrative | 15,584 | 12,560 | 47,265 | 37,802 |
| Provision for (recovery of) loan losses and other reserves | 2,368 | -240 | 104,600 | -640 |
| Impairment of real estate |  | 2,571 | 440 | 6,674 |
| Total expenses | 214,852 | 161,957 | 694,817 | 453,665 |
| **Other (expense) income:** | | | | |
| Loss on extinguishment of debt |  | -1,154 |  | -1,154 |
| Other (expense) income | -250 | -769 | -2,988 | 13,978 |
| Net (loss) gain on sales of real estate | -8,065 | -4,430 | 29,652 | 5,544 |
| Total other (expense) income | -8,315 | -6,353 | 26,664 | 18,368 |
| Income before income from unconsolidated joint ventures and income tax expense | 26,398 | 21,727 | 39,031 | 127,433 |
| Income from unconsolidated joint ventures | 2,230 | 1,226 | 6,366 | 2,276 |
| Income tax expense | -71 | -436 | -1,275 | -1,346 |
| Net income | 28,557 | 22,517 | 44,122 | 128,363 |
| Net loss attributable to noncontrolling interests | 50 | 21 | 163 | 21 |
| Net income attributable to Sabra Health Care REIT, Inc. | 28,607 | 22,538 | 44,285 | 128,384 |
| **Net income attributable to Sabra Health Care REIT, Inc., per:** | | | | |
| Basic common share | 0.11 | 0.09 | 0.17 | 0.54 |
| Diluted common share | 0.11 | 0.09 | 0.17 | 0.53 |
| Weighted average number of common shares outstanding, basic | 255,604,032 | 239,896,059 | 253,348,731 | 238,595,147 |
| Weighted average number of common shares outstanding, diluted | 259,823,331 | 243,558,449 | 257,186,896 | 241,593,992 |

##### Income Statement (Three Months Ended September 30, — (dollars in thousands, except per share data))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Net income attributable to Sabra Health Care REIT, Inc. | 28,607 | 22,538 | 44,285 | 128,384 |
| **Add:** | | | | |
| Depreciation and amortization of real estate assets | 64,779 | 48,511 | 174,289 | 135,591 |
| Depreciation and amortization of real estate assets related to noncontrolling interests | -124 | -40 | -368 | -40 |
| Depreciation and amortization of real estate assets related to unconsolidated joint ventures | 1,474 | 1,722 | 4,478 | 5,945 |
| Net loss (gain) on sales of real estate | 8,065 | 4,430 | -29,652 | -5,544 |
| Impairment of real estate |  | 2,571 | 440 | 6,674 |
| FFO attributable to Sabra Health Care REIT, Inc. | 102,801 | 79,732 | 193,472 | 271,010 |
| Write-offs of straight-line rental income receivable and lease intangibles | 6,200 | 9,237 | 4,796 | 7,759 |
| Lease termination (income) expense, net |  | -1,518 | 2,873 | -1,518 |
| Loss on extinguishment of debt |  | 1,154 |  | 1,154 |
| Provision for (recovery of) loan losses and other reserves | 2,368 | -240 | 103,327 | -640 |
| Other normalizing items (1) | -9,012 | 270 | -8,410 | -14,166 |
| Normalized FFO attributable to Sabra Health Care REIT, Inc. | 102,357 | 88,635 | 296,058 | 263,599 |
| FFO attributable to Sabra Health Care REIT, Inc. | 102,801 | 79,732 | 193,472 | 271,010 |
| Stock-based compensation expense | 3,922 | 2,875 | 11,109 | 8,290 |
| Non-cash rental and related revenues | 4,248 | 7,151 | -1,005 | 820 |
| Non-cash interest expense | 2,372 | 2,153 | 7,110 | 5,608 |
| Non-cash portion of loss on extinguishment of debt |  | -1,730 |  | -1,730 |
| Provision for (recovery of) loan losses and other reserves | 2,368 | -240 | 103,327 | -640 |
| Other adjustments related to unconsolidated joint ventures | 76 | 218 | 229 | 237 |
| Other adjustments (2) | 821 | 547 | 1,966 | -15,535 |
| AFFO attributable to Sabra Health Care REIT, Inc. | 116,608 | 90,706 | 316,208 | 268,060 |
| Lease termination (income) expense, net |  | -1,518 | 2,873 | -1,518 |
| Cash portion of loss on extinguishment of debt |  | 2,884 |  | 2,884 |
| Other normalizing items (1) | -9,359 | 81 | -8,430 | 2,619 |
| Normalized AFFO attributable to Sabra Health Care REIT, Inc. | 107,249 | 92,153 | 310,651 | 272,045 |
| **Amounts per diluted common share attributable to Sabra Health Care REIT, Inc.:** | | | | |
| Net income | 0.11 | 0.09 | 0.17 | 0.53 |
| FFO | 0.4 | 0.33 | 0.75 | 1.12 |
| Normalized FFO | 0.39 | 0.36 | 1.15 | 1.09 |
| AFFO | 0.45 | 0.37 | 1.22 | 1.1 |
| Normalized AFFO | 0.41 | 0.38 | 1.2 | 1.12 |

##### Balance Sheet (September 30, 2026 — (dollars in thousands, except per share data))

| | September 30, 2026 | December 31, 2025 |
|---|---:|---:|
| **Assets** | | |
| Real estate investments, net of accumulated depreciation of $1,322,145 and $1,224,663 as of September 30, 2026 and December 31, 2025, respectively | 4,925,213 | 4,686,377 |
| Loans receivable and other investments, net | 120,295 | 434,100 |
| Investment in unconsolidated joint ventures | 114,631 | 118,166 |
| Cash and cash equivalents | 36,240 | 71,537 |
| Restricted cash | 6,842 | 6,603 |
| Lease intangible assets, net | 87,180 | 65,321 |
| Accounts receivable, prepaid expenses and other assets, net | 139,551 | 111,292 |
| Total assets | 5,429,952 | 5,493,396 |
| **Liabilities** | | |
| Secured debt, net | 41,706 | 43,275 |
| Revolving credit facility | 126,503 | 217,584 |
| Term loans, net | 1,030,224 | 1,032,311 |
| Senior unsecured notes, net | 1,237,543 | 1,235,726 |
| Accounts payable and accrued liabilities | 135,005 | 119,329 |
| Lease intangible liabilities, net | 17,696 | 21,383 |
| Total liabilities | 2,588,677 | 2,669,608 |
| **Equity** | | |
| Common stock, $0.01 par value; 500,000,000 shares authorized, 261,961,461 and 251,697,456 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 2,620 | 2,517 |
| Additional paid-in capital | 5,014,619 | 4,836,270 |
| Cumulative distributions in excess of net income | -2,200,671 | -2,013,375 |
| Accumulated other comprehensive income (loss) | 23,083 | -3,571 |
| Total Sabra Health Care REIT, Inc. stockholders’ equity | 2,839,651 | 2,821,841 |
| Noncontrolling interests | 1,624 | 1,947 |
| Total equity | 2,841,275 | 2,823,788 |
| Total liabilities and equity | 5,429,952 | 5,493,396 |

##### Cash Flow (Nine Months Ended September 30, — (in thousands))

| | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| **Cash flows from operating activities:** | | |
| Net income | 44,122 | 128,363 |
| **Adjustments to reconcile net income to net cash provided by operating activities:** | | |
| Depreciation and amortization | 174,289 | 135,591 |
| Non-cash rental and related revenues | -1,005 | 820 |
| Non-cash interest expense | 7,110 | 5,608 |
| Stock-based compensation expense | 11,109 | 8,290 |
| Loss on extinguishment of debt |  | 1,154 |
| Provision for (recovery of) loan losses and other reserves | 104,600 | -640 |
| Net gain on sales of real estate | -29,652 | -5,544 |
| Impairment of real estate | 440 | 6,674 |
| Income from unconsolidated joint ventures | -6,366 | -2,276 |
| Distributions of earnings from unconsolidated joint ventures | 5,814 | 5,917 |
| Other non-cash items |  | -17,183 |
| **Changes in operating assets and liabilities:** | | |
| Accounts receivable, prepaid expenses and other assets, net | -16,449 | -9,129 |
| Accounts payable and accrued liabilities | 19,140 | 3,541 |
| Net cash provided by operating activities | 313,152 | 261,186 |
| **Cash flows from investing activities:** | | |
| Acquisition of real estate and lease intangibles | -516,346 | -301,563 |
| Origination and fundings of loans receivable | -994 | -5,710 |
| Origination and fundings of preferred equity investments | -2,612 | -9 |
| Additions to real estate | -41,058 | -24,183 |
| Escrow deposits for potential investments | -60 | -500 |
| Repayments of loans receivable | 210,743 | 15,442 |
| Repayments of preferred equity investments | 2,897 | 1,977 |
| Investment in unconsolidated joint ventures |  | -1,241 |
| Net proceeds from the sales of real estate | 156,860 | 43,087 |
| Proceeds from net investment hedges |  | 4,462 |
| Insurance proceeds | 136 | 1,267 |
| Distributions in excess of earnings from unconsolidated joint ventures |  | 5,557 |
| Net cash used in investing activities | -190,434 | -261,414 |
| **Cash flows from financing activities:** | | |
| Net (repayments of) borrowings from revolving credit facility | -90,200 | 174,805 |
| Principal payments on senior unsecured notes |  | -500,000 |
| Proceeds from term loans |  | 500,000 |
| Principal payments on secured debt | -1,604 | -1,562 |
| Payments of deferred financing costs | -111 | -4,405 |
| Payments related to extinguishment of debt |  | -2,884 |
